A mid-sized pharmaceutical company faced urgent FDA feedback tied to a product label expansion, requiring a full protocol for a non-interventional retrospective study in a rare endocrine disorder. Worldwide built delivery around quality content, effective communication, and agile execution, using the EnCePP checklist to align with global research writing standards, streamlining supplementary materials for efficient review, and preparing a customized no-objection letter that addressed data privacy and governance. Cross-functional subject matter experts resolved sponsor questions within one business day, and Worldwide delivered a draft regulatory-compliant protocol in three days. With protocol development and regulatory alignment completed in just over a month, the study start was enabled ahead of schedule. This boosted the sponsor’s confidence in the team’s ability to deliver independently while reducing the oversight burden.
Read the full case study to learn how Worldwide translated urgent FDA feedback into a compliant protocol, resolved issues without creating more oversight, and kept cross-functional contributors aligned.
